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Abstract
Background: Glioblastoma Multiforme (GBM) is a malignant primary brain tumor in which the standard treatment,
ionizing radiation (IR), achieves a median survival of about 15 months. GBM harbors glioblastoma stem-like cells
(GSCs), which play a crucial role in therapeutic resistance and recurrence.
Methods: Patient-derived GSCs, GBM cell lines, intracranial GBM xenografts, and GBM sections were used to
measure mRNA and protein expression and determine the related molecular mechanisms by qRT-PCR, immunoblot,
immunoprecipitation, immunofluorescence, OCR, ECAR, live-cell imaging, and immunohistochemistry. Orthotopic
GBM xenograft models were applied to investigate tumor inhibitory effects of glimepiride combined with
radiotherapy.
Results: We report that GSCs that survive standard treatment radiation upregulate Speedy/RINGO cell cycle
regulator family member A (Spy1) and downregulate CAP-Gly domain containing linker protein 3 (CLIP3, also
known as CLIPR-59). We discovered that Spy1 activation and CLIP3 inhibition coordinately shift GBM cell glucose
metabolism to favor glycolysis via two cellular processes: transcriptional regulation of CLIP3 and facilitating Glucose
transporter 3 (GLUT3) trafficking to cellular membranes in GBM cells. Importantly, in combination with IR,
glimepiride, an FDA-approved medication used to treat type 2 diabetes mellitus, disrupts GSCs maintenance and
suppresses glycolytic activity by restoring CLIP3 function. In addition, combining radiotherapy and glimepiride
significantly reduced GBM growth and improved survival in a GBM orthotopic xenograft mouse model.
Conclusions: Our data suggest that radioresistant GBM cells exhibit enhanced stemness and glycolytic activity
mediated by the Spy1-CLIP3 axis. Thus, glimepiride could be an attractive strategy for overcoming radioresistance
and recurrence by rescuing CLIP3 expression.
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Background
Glioblastoma Multiforme (GBM) remains the most
aggressive and non-curative malignant primary brain
tumor in adults [1]. Current therapy entails surgical re-
section followed by radiotherapy with chemotherapy to
eliminate highly proliferating tumor cells [2]. Median
survival is approximately 15 months, and the overall sur-
vival rate has not significantly improved over the past
20 years [3]. Recently, GBM was classified into four sub-
types (classical, neural, proneural, and mesenchymal)
based on genetic and clinical profiles [4]. Although this
knowledge helps predict prognosis of patients and re-
sponse to therapy, personalized treatments or novel
therapeutic curative strategies are urgently needed. At a
cellular level, glioblastomas are viewed as hierarchies
with glioblastoma stem-like cells (GSCs) capable of self-
renewal and tumorigenic capacity at the apex, and giving
rise to differentiated tumor cell types [5]. GSCs are de-
fined by sustained proliferation, sphere formation cap-
ability, multilineage differentiation, rewired metabolism,
and resistance to cytotoxic therapies including ionizing
radiation (IR) [6]. However, conventional therapies rarely
impact on the stemness of GSCs, but instead boosts
their preferential survival and adaptation of stem-like
cell properties by non-GSCs [7, 8]. Therefore, therapy-
enriched GSCs contribute not only to tumor growth but
also to tumor recurrence after chemoradiotherapy. Al-
though targeting GSCs holds great promise as a thera-
peutic strategy for eradicating GBM, identifying cellular
mechanisms that eliminate GSCs while sparing healthy
cells and tissues has been met with little success to date,
and no such drug are available in clinical practice [6, 9].
Speedy/RINGO cell cycle regulator family member A
(Spy1), a member of Speedy/RINGO family, was re-
ported to regulate GSCs division by directly binding to
and activating cyclin-dependent kinases (CDKs), inde-
pendently of phosphorylation, and bypassing cell cycle
checkpoints [10]. A recent study showed that Spy1 ex-
pression was significantly elevated in GBM relative to
low-grade glioma tissues, suggesting that Spy1 might
contribute to processes that increase GSC populations in
higher-grade gliomas [10, 11]. According to the study,
Spy1 interacted with CLIPR59/CLIP3 (CAP-Gly domain
containing linker protein 3, hereafter referred to as
CLIP3), a membrane-associated protein with several
protein-protein interaction domains reported to regulate
glucose homeostasis [12]. In addition, the Spy1/CLIPR-3
interaction was proposed to confer resistance to TNF-α-
induced apoptosis in GBM, a plausible mechanism by
which GSCs could escape cell death induced by IR. Be-
yond negative correlation between CLIP3 and Spy1 ex-
pression in GBM tissues, few studies provide insight into
how their interaction affect cellular processes. A recent
study found that CLIP3 via TBC1 domain family
member 4 (TBC1D4) modulates membrane transloca-
tion of Glucose transporter 4 (GLUT4) in adipocytes,
pointing to a role in dynamic intracellular transport to
the cell membrane [13]. Although CLIP3 is mainly
expressed in the human brain, its relationship with brain
glucose transporter GLUT1 and GLUT3 has not been
studied. Given the molecular connections reported in
the literature, and the role of Spy1 in GSC cell division,
we hypothesized that a Spy1-CLIP3 axis could play im-
portant roles in GBM malignancy by regulating GSC
proportion and GSC-specific glucose metabolism.
Cancer cells and especially cancer stem cells (CSCs)
highjack control of metabolism to favor aerobic glycoly-
sis rather than oxidative phosphorylation for ATP gener-
ation, which is known as the Warburg effect [14]. The
metabolic reprogramming enables cancer cells to pro-
duce biological building blocks required for cell prolifer-
ation [15]. In brain cancer, the Warburg effect is
considered more important because the brain is mostly
fueled by glucose [16]. In GBM, several drugs that se-
lectively target general metabolic pathways have been
tested in clinical trials, while only a small proportion of
the drugs regulate glucose metabolism with clinical sig-
nificance [17]. Our previous study found increased glu-
cose uptake in highly glycolytic GBM cells, consistent
with the low ATP production efficiency of glycolysis
leading to cellular increase GLUT expression to achieve
a higher glucose uptake [18]. The major GLUT in GBM
is GLUT1, but GSCs also express GLUT3, which has five
times higher affinity for glucose than GLUT1, to adapt
to high glucose demands [19]. Previously, glucose uptake
was thought to be regulated by GLUT expression, but
our understanding of how regulated cell surface traffick-
ing impacts dynamics of glucose uptake is increasing
[20, 21]. Translocation of GLUT1 to the plasma mem-
brane is primarily controlled by autophagy-dependent
recycling and whereas that of GLUT3 is controlled by
the ras-related protein Rab-11A (Rab11a), which is the
only known marker of its trafficking, to form Rab11a-
positive recycling endosome [22, 23]. However, how
membrane translocation of GLUTs might contribute to
GBM etiology and recurrence remains unknown.
Temozolomide (TMZ), a first-line treatment for GBM,
alkylates DNA bases and leads to DNA mismatch, inhib-
ition of DNA replication, and cytotoxicity in highly pro-
liferating cells [24]. However, approximately 50% of
TMZ-treated GBM patients do not respond to TMZ be-
cause their tumors overexpressed O6-Methylguanine-
DNA Methyltransferase (MGMT), and most patients ex-
perience serious side effects including bone marrow sup-
pression and female infertility [25–27]. Despite these
limitations, TMZ is the only drug that improves survival
in GBM when combined with radiotherapy [28]. Al-
though many studies have suggested novel molecular
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targets for GBM therapy, most drugs have clinically
failed due to high toxicity or lack of efficacy [29]. Given
the timelines and costs associated with bringing a new
drug to the clinic, drug repositioning is emerging as a
strategy for drug discovery [30]. Drugs that have demon-
strated safety in patients, but failed efficacy endpoints in
a specific indication, might become attractive thera-
peutic strategies if the existing drugs can specifically tar-
get biomarkers in other diseases. Based on this
background, we hypothesized that a CLIP3-activating
drug which has already been approved by the FDA suc-
cessfully targets self-renewal and metabolic pathway
mechanism of GBM, distinct from the current treatment
approaches which solely target cell proliferation.
Materials and methods
Chemicals, antibodies, and reagents
Glimepiride and glibenclamide were obtained from
Tokyo Chemical Industry (Tokyo, Japan). Antibodies
specific for Spy1 and CLIP3 were purchased from
Abcam (Cambridge, MA, USA); antibodies specific for
β-actin, HSP90, CDK2, HA-probe, and GLUT3 were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA); an antibody specific for CD133-PE were pur-
chased from Miltenyi Biotec (Bergisch Gladbach,
Germany). Phosphate Buffered Saline (PBS), Hank’s Bal-
anced Salt Solution (HBSS), Eagle’s Minimum Essential
Medium (MEM), Dulbecco’s Modified Eagle Medium/
Nutrient Mixture F-12 (DMEM/F-12), fetal bovine
serum (FBS), B27 Supplement (minus vitamin A), basic
fibroblast growth factor (bFGF), epidermal growth factor
(EGF), L-glutamine, sodium pyruvate, penicillin, strepto-
mycin, and Trizol were purchased from Thermo Fisher
Scientific (Cleveland, OH, USA). Collagenase D and
DNase I recombinant were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Control siRNA and
siRNA specific for Spy1, CLIP3, NRF1, CDK2, CD133,
NES, and Kir6.2 were purchased from Bioneer (Daejeon,
Republic of Korea). pGL3-NFAT luciferase vector was
purchased from Addgene (Watertown, MA, USA); a
plasmid for NRF1 was purchased from Origene (Rock-
ville, MD, USA); a plasmid for Spy1-HA was purchased
from Nova Lifetech (Singapore); plasmids for CLIP3,
Rab11a-OFP, and GLUT3-GFP were purchased from
Sino Biological (Beijing, China).
Glioblastoma stem cell derivation
Patient-derived GSC11 glioblastoma stem cells were pro-
vided by Dr. Frederick F. Lang (Department of Neuro-
surgery, The University of Texas, M. D. Anderson
Cancer Center, Houston, USA); patient-derived BCL20-
HP01 and BCL20-HP02 glioblastoma stem cells were
obtained from patients undergoing resection in accord-
ance with a protocol approved by Haeundae Paik
Hospital (Inje University, Busan, Republic of Korea);
patient-derived TS19–176 glioblastoma stem cells were
transferred via a material transfer agreement from Sever-
ance Hospital. BCL20-HP01 GSCs were derived from a
GBM from a 47-year old male patient. BCL20-HP02
GSCs were derived from a GBM from a 38-year old male
patient. Detailed information of the patients is summa-
rized in Table S1. More specifically, after the resection,
about 200 to 500 mg of tumor samples were collected
into a tube containing DMEM/F-12 supplemented with
B27. Tumor specimen was then washed with 5 ml of
HBSS to remove blood and debris. After the washing,
the tumor was cut into small fragments and minced with
a sterile scalpel blade into approximately 1 mm3 frag-
ment. To dissociate GBM tumor tissue, the minced
tumor was treated with collagenase D (1mg/ml) and
DNase I (0.1 mg/ml) in HBSS and incubated at 37 °C for
30 to 90min with gentle mixing. Finally, the solution
was passed through the 70 μm sterile mesh filter to re-
move any large, undigested tumor pieces. To culture
cells as tumorspheres, the patient-derived glioblastoma
stem cells were cultured in DMEM/F-12 supplemented
with B27, EGF (20 ng/ml), bFGF (20 ng/ml), penicillin-
streptomycin (10,000 U/ml) at 37 °C in a humidified at-
mosphere of 95% air and 5% CO2.
Cell lines, cell culture, and irradiation
U87MG, T98G cell lines were obtained from the Korea
Cell Line Bank (KCLB, Seoul, Republic of Korea). The
phenotypes of these cell lines have been authenticated
by the KCLB. All cells were free of mycoplasma contam-
ination and were authenticated by short tandem repeat
profiling within the past 12 months. U87MG-luciferase
expressing cells were transferred via a material transfer
agreement from Severance Hospital (Yonsei University,
Seoul, Republic of Korea). The cells were grown in
MEM supplemented with 10% FBS, penicillin (100 U/
ml), and streptomycin (100 mg/ml) at 37 °C in a humidi-
fied atmosphere of 95% air and 5% CO2. The cells were
exposed to a single dose of X-ray using an X-ray gener-
ator M-150WE (Softex, Tokyo, Japan) at a dose rate of
0.38 Gy/min.
Animal care protocol and orthotopic xenograft mouse
model
Six-week-old male BALB/c athymic nude mice (Orient
Bio, Seongnam, Republic of Korea) were used for gener-
ating xenograft mouse model following the previous
study [18]. All experiments were performed in accord-
ance with the provisions of the NIH Guide for the Care
and Use of Laboratory Animals. The mice were housed
individually or in groups of up to five in sterile cages,
and were maintained in animal care facilities in a
temperature regulated room (23 ± 1 °C) with a 12 h
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light–dark cycle. All animals were fed water and stand-
ard mouse chow ad libitum. U87MG-luciferase express-
ing cells were harvested through trypsinization and
suspended at a density of 1 × 105 cells per μl in serum-
free media. Then, 5 × 105 cells were injected into the
mice brains using stereotactic surgery. 18 days after the
injection date, the mice brains were irradiated with 2 Gy
daily for five days at a dose rate of 600 MU/min using a
TrueBeam STx (Varian Medical Systems, Palo Alto, CA,
USA). Xenograft growth was monitored by biolumines-
cent imaging using VISQUE Invivo Smart LF (Vieworks,
Anyang, Republic of Korea). Mice were sacrificed upon
manifestation of neurological symptoms.
Immunofluorescence and live-cell imaging
Cells were fixed in 4% paraformaldehyde at room
temperature for 20min and permeabilized with 0.5% Triton
X-100 for 10min. Subsequently, cells were rinsed three times
with PBS, and blocked in blocking buffer (0.1% BSA in PBS)
for 30min. Cells were incubated overnight with the specific
primary antibodies at 4 °C, and washed three times with
PBS. After being incubated with DyLight 488- or 594-
conjugated secondary antibodies (Thermo Scientific), cells
were mounted with Fluoroshield Mounting Medium with
DAPI (Abcam). Fluorescent images were visualized using a
Leica DMi 8 fluorescence microscope (Leica, Wetzlar,
Germany). For live cell imaging, cells were grown on glass
bottom dishes and treated with CLIP3 siRNA or IR. Intracel-
lular GFP-tagged GLUT3 dynamics in live cells were imaged
in an environmentally controlled chamber at 37 °C for the
indicated times using LSM 800 confocal microscope (ZEISS,
Oberkochen, Germany). The images were analyzed with
ZEN software (ZEISS). For analysis of all microscopy images,
raw image data were used.
Total RNA isolation and qRT-PCR
For mRNA expression assessment, qRT-PCR was per-
formed following the previous study [31]. Briefly, RNA
was isolated with Trizol following the manufacturers’ in-
structions and real-time qRT-PCR was performed using
an Applied Biosystems StepOne Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). It was per-
formed for 40 cycles of 95 °C for 15 s and 60 °C for 1 min
followed by thermal denaturation. The expression of
each gene relative to GAPDH mRNA was determined
using the 2-ΔΔCt method. The sequences of the primers
used are listed in Supplementary Table S2. Each sample
was assessed by triplication.
Western blotting and immunoprecipitation (IP)
The protein expression was validated as previously de-
scribed [32]. Briefly, whole cell lysates (WCL) were pre-
pared using radioimmunoprecipitation assay (RIPA) lysis
buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-
100, 25 mM NaF, 1 mM dithiothreitol, and 20 mM ethyl-
ene glycol tetraacetic acid supplemented with protease
inhibitors) and the protein concentrations were deter-
mined using a BioRad protein assay kit (BioRad Labora-
tories, Hercules, CA, USA). Protein samples were
subjected to SDS-PAGE, transferred to a nitrocellulose
membrane and then blocked with 5% bovine serum
albumin in tris-buffered saline with Tween 20 (10 mM
Tris, 100 mM NaCl, and 0.1% Tween 20). The mem-
branes then were probed using the specific primary anti-
bodies and peroxidase-conjugated secondary antibodies
from Santa Cruz Biotechnology. For all western immu-
noblot experiments, blots were imaged using an ECL
detection system (Roche Applied Science, Indianapolis,
IN, USA) with iBright FL1000 Imaging System from
Thermo Fisher Scientific. For IP studies, we prepared
lysates for protein samples obtained from treatment of
non-denaturing buffer (50 mM Tris, pH 8.0, 150 mM
NaCl, 1% NP-40, 50 mM NaF, 100 μM Na3VO4, 50 μM
PMSF, 2 μg/ml Aprotinin, 1 μg/ml Leupeptin) for 30 min
at 4 °C, or treatment of denaturing buffer (50 mM Tris,
pH 8.0, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% so-
dium deoxycholate, 50 mM NaF, 100 μM Na3VO4,
50 μM PMSF, 2 μg/ml Aprotinin, 1 μg/ml Leupeptin) for
5 min at 95 °C. The lysates for protein samples were
immunoprecipitated overnight with the specific primary
antibodies and protein A/G agarose beads (Santa Cruz
Biotechnology). After washing with the lysis buffer, im-
munoprecipitates were then boiled in 2 × SDS sample
buffer for 10 min, followed by centrifugation. They were
detected by Western blot analysis.
Luciferase reporter gene assay
Genomic region harboring CLIP3 promoter (300 bp up-
stream of the transcription start site of the gene) was
cloned into pGL3-NFAT luciferase vector digested by
MluI and HindIII. The sequences of the wild-type or
mutant CLIP3 promoter are listed in Supplementary
Table S3. A luciferase assay was performed as previously
reported [33]. Briefly, luciferase activity was measured
using Luciferase Assay System from Promega (Madison,
WI, USA). Cells were seeded in 60mm culture dishes 1
day before transfection. At 48 h after transfection, media
was removed and the dishes were washed by PBS. 400 μl
of Cell Culture Lysis Reagent was added to the dishes
directly and transferred to new tubes. After brief centri-
fugation, 20 μl of cell lysate was mixed with 100 μl of
Luciferase Assay Reagent. Luminescence was measured
using a Glomax multi detection system (Promega).
Flow cytometry
The expression of the molecular marker CD133 in the
various cell cultures was detected using an anti-CD133-
PE antibody. Cells were gently disaggregated to single-
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cell suspensions by trypsin, and stained with CD133-PE
for 30 min in the dark at 4 °C. The stained cells were
then detected using a FACSVerse flow cytometer (BD
Biosciences, San Jose, CA, USA).
In vitro limiting dilution neurosphere formation assay
For in vitro limiting dilution assays, decreasing numbers
of cells per well (500, 200, 100, 50, 20, and 10) were
plated into 96-well plates. The presence and number of
neurospheres in each well were recorded 10 days after
plating. Extreme limiting dilution analysis was
performed using software available at http://bioinf.wehi.
edu.au/software/elda [34].
Measurement of OCR and ECAR
Oxygen consumption rate (OCR) and extracellular acidifica-
tion rate (ECAR) were measured by Seahorse XFp Analyzer
(Agilent Technologies, Santa Clara, CA, USA) with 80–90%
confluent cells following the previous study [18]. Briefly, on
the day following cell seeding and treatment of siRNA or gli-
mepiride, cells were equilibrated for 1 h in a non-CO2 incu-
bator. For the OCR assay, the media were changed to the XF
assay media (Agilent Technologies). Injection port A on the
sensor cartridge was loaded with oligomycin (2 μM), port B
was loaded with FCCP (1 μM), and port C was loaded with
rotenone/antimycin A (1 μM each). For the ECAR assay, the
media were changed to the XF assay media (Agilent Tech-
nologies) without glucose. The injection port A was loaded
with glucose (10mM), port B was loaded with oligomycin
(2 μM), and port C was loaded with 2-Deoxy-D-glucose
(100mM). A minimum of three wells were utilized per con-
dition to calculate OCR and ECAR.
Metabolic assays
Metabolic assays were performed following the previous
study [18]. In brief, glucose uptake, lactate production,
and the levels of G3P, serine, fumarate, malate, and ATP
were measured using assay kits from BioVision (San
Francisco, CA, USA). NADP+/NADPH ratio and the
levels of citrate and succinate were determined using
assay kits from Abcam.
Cell viability assay and colony-forming assay
For cell viability assay, cells were seeded at 10,000 cells per
well in 96-well plates 1 day before the addition of glimepiride
and/or IR for 48 h. Cell viability was determined using
CellTiter-Glo® Luminescent Viability Assay kit (Promega).
Colony-forming assay was performed following the previous
study [35]. Briefly, the cells were seeded at a density of 600
cells in 35-mm culture dishes. After 24 h, the cells were
treated with glimepiride and/or IR. 14 days after seeding, the
cells were fixed with 10% methanol and 10% acetic acid,
which were then stained with 1% crystal violet. Colonies
containing more than 50 cells were identified using densi-
tometry software and scored as survivors.
Hematoxylin and eosin (H&E) staining and
immunohistochemistry (IHC)
H&E staining and IHC were performed as previously de-
scribed [36]. The brain samples were embedded in paraf-
fin blocks, and the sections were prepared by HistoCore
AutoCut (Leica, Deerfield, IL, USA). Next, the sections
were cut into 4 μm sections and stained with H&E, fol-
lowing standard procedures. For IHC, sections were
treated with 3% hydrogen peroxide/methanol and then
with 0.25% pepsin to retrieve antigens. Next, samples
were incubated in blocking solution (Dako, Carpinteria,
CA, USA), after which they were incubated at 4 °C over-
night with the specific primary antibodies diluted in the
antibody diluent (Dako). The sections were subsequently
washed with tris buffered saline with 0.1% Tween 20 and
then incubated with polymer-horseradish peroxidase-
conjugated secondary antibody (Dako). A 3,3′-diamino-
benzidine substrate chromogen system (Dako) was uti-
lized to detect antibody binding. Stained sections were
observed under an Olympus IX71 inverted microscope
(Olympus Optical, Tokyo, Japan).
Statistical analysis
All numerical data are presented as the means ± stand-
ard error of the mean from at least three independent
experiments. For quantifications, two-tail unpaired Stu-
dent’s t-test was used for comparing two experimental
groups, and one-way ANOVA was applied when needed
to compare three or more experimental groups. Log-
rank (Mantel-Cox) test was used for statistical analysis
of survival. The Prism 9 software (GraphPad Software,
San Diego, CA, USA) was used for all statistical analyses.
A p-value < 0.05 was considered to be statistically
significant.
Results
GBM cells acquire radioresistance by CLIP3
downregulation
We previously established a GBM orthotopic xenograft
mouse model in which we analyzed gene expression of
cells that survived cranial radiation (2 Gy/day for 5 days)
(GEO accession number: GSE117126) [18]. Of the vari-
ous genes analyzed, genes related to stemness or glucose
metabolism were the most highly upregulated in surviv-
ing cells relative to control cells, and were hence consid-
ered the most relevant to conferring radioresistance and
tumor recurrence. Within the categories ‘multicellular
organism development’ and ‘Regulation of glucose trans-
membrane transport’ ontologies, we decided to focus on
Spy1 and CLIP3 based on their inverse expression pat-
tern and the published literature (Fig. 1A); Spy1
Kang et al. Journal of Experimental & Clinical Cancer Research          (2021) 40:282 Page 5 of 18
expression increased in irradiated GBM cells, while
CLIP3 expression decreased. We hypothesized that as
Spy1 and CLIP3 altered expression was induced by radi-
ation and conferred radioresistance, these two proteins
would regulate mechanism that could be therapeutically
targeted. According to the TCGA data of the 152
GBM patients, Spy1 and CLIP3 gene expression levels
were negatively correlated (Fig. 1B). Likewise, Spy1
expression was greatly upregulated in GBM patients
in comparison to normal brain tissues or low-grade
Fig. 1 GBM cells acquire radioresistance by CLIP3 downregulation. A cDNA microarray analysis was performed in orthotopic xenograft GBM
tumor sections from control and IR (2 Gy × 5) groups. B, C The gene expression profiles and clinical data were collected from The Cancer
Genome Atlas (TCGA) database available through Gliovis [37]. B Correlation of mRNA expression levels between Spy1 and CLIP3 in 152 GBM
patients (RNA Seq V2 RSEM). C mRNA expression levels of Spy1 and CLIP3 were investigated in 10 non-tumor tissues and 528 GBM tissues (upper
panel), and in 515 low-grade glioma and 152 GBM tissues (lower panel). D Survival rate calculated by the Kaplan-Meier survival curve in GBM
patients separated according to median expression level of Spy1 and CLIP3. E mRNA levels of Spy1 and CLIP3 were analyzed by real-time qRT-
PCR at 6, 12, and 24 h after IR (6 Gy) in U87MG and T98G cells. F Protein levels of Spy1, CLIP3, and β-actin were analyzed by western blot at 6, 12,
24, and 36 h after IR (6 Gy) in U87MG and T98G cells. G mRNA levels of Spy1 and CLIP3 were analyzed by real-time qRT-PCR at 6, 12, and 24 h
after IR (6 Gy) in GSC11, BCL20-HP01, and TS19–176 cells. H Protein levels of Spy1, CLIP3, β-actin, and HSP90 were analyzed by western blot at 6,
12, 24, and 36 h after IR (6 Gy) in GSC11, BCL20-HP01, and TS19–176 cells. Statistical analysis was performed with one-way ANOVA plus a Tukey’s
multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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glioma tissues, while CLIP3 expression was highly
downregulated in GBM tissues (Fig. 1C). In addition,
both Spy1 and CLIP3 functioned as biomarkers; Spy1
expression informed poor prognosis, whereas CLIP3
expression correlated positively with patient outcomes
(Fig. 1D and S1A).
To examine gene expression profiles of cells that
survive IR in vitro, we measured Spy1 and CLIP3 ex-
pression levels in two GBM cell lines (U87MG and
T98G) in time course experiments upon IR (6 Gy)
(Fig. 1E and F). Spy1 expression increased shortly
after IR (6, 12 h), while CLIP3 expression was con-
stantly decreased at both mRNA and protein levels.
In addition, IR in three patient-derived glioblastoma
stem cell lines (GSC11, BCL20-HP01, and TS19–176)
resulted in similar Spy1 and CLIP3 expression level
changes (Fig. 1G and H). Taken together, we rea-
soned that IR exposure-induced upregulation of Spy1
and downregulation of CLIP3 contributed to the
radioresistance acquisition of surviving GBM cells.
Fig. 2 Spy1 negatively regulates the transcriptional activity of CLIP3 by CDK2/NRF1 signaling. A mRNA and protein levels of Spy1 and CLIP3 were
analyzed by real-time qRT-PCR and Western blot, respectively, upon Spy1 siRNA treatment in U87MG and T98G cells. B A possible NRF1 binding
site on the CLIP3 promoter was predicted using GeneCards database (https://www.genecards.org/). NRF1 was expected to bind − 24 to − 14
(GCGCATGCGCA) from the transcription start site (TSS) of CLIP3. C mRNA and protein levels of NRF1 and CLIP3 were analyzed by real-time qRT-
PCR and Western blot, respectively, upon NRF1 siRNA treatment in U87MG and T98G cells. D Luciferase activity was measured upon transfection
of pGL3-NFAT-luc plasmids, including wild-type (CLIP3-Luc) or mutant CLIP3 (CLIP3 mut-Luc) promoter linked to luciferase gene, in the absence
or presence of transfection of NRF1 gene in U87MG and T98G cells. E Western blot with CDK2 or HA antibodies after immunoprecipitation of
Spy1 from U87MG and T98G whole cell lysates at 12 and 24 h after IR (3 or 6 Gy) using a HA antibody. Protein levels of CDK2, Spy1, and β-actin
in the whole cell lysates were analyzed at 12 and 24 h after IR (3 or 6 Gy) by western blot. F A schematic diagram illustrates that Spy1 negatively
regulates CLIP3 through CDK2/NRF1 signaling. G Luciferase activity was measured upon transfection of the pGL3-NFAT-luc plasmids with Spy1
gene, CDK2 siRNA, or NRF1 siRNA treatment in U87MG and T98G cells. Statistical analysis was performed with Student’s t-test for (A) and (C), and
one-way ANOVA plus a Tukey’s multiple comparisons test for (D) and (G). *p < 0.05, **p < 0.01, ****p < 0.0001
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Spy1 negatively regulates the transcriptional activity of
CLIP3 by CDK2/NRF1 signaling
To investigate whether the negative correlation be-
tween Spy1 and CLIP3 represented causation, we ex-
perimentally tested whether a transient increase of
Spy1 after IR reduces CLIP3 transcription levels. As
shown in Fig. 2A, knockdown of Spy1 increased
CLIP3 mRNA and protein level in GBM cell lines.
When we used GeneCards database to identify poten-
tial upstream regulator of CLIP3 transcription, we
found that nuclear respiratory factor 1 (NRF1) was
top-ranked (Fig. 2B). Accordingly, knockdown of
NRF1 dramatically decreased CLIP3 mRNA and pro-
tein level in GBM cell lines, implying that NRF1 is a
transcriptional activator of CLIP3 (Fig. 2C). To verify
that NRF1 directly binds to the promoter region of
CLIP3, we transfected pGL3-NFAT-luc plasmids
(wild-type or mutant CLIP3 promoter linked to lucif-
erase gene) in the absence or presence of NRF1 gene
transfection, and measured luciferase activity in GBM
cell lines (Fig. 2D). Indeed, we found that luciferase
activity was increased with the wild-type CLIP3 pro-
moter upon transfection of NRF1, while it hardly
changed with the mutant CLIP3 promoter. In
addition, the luciferase activity with the CLIP3 mut-
Luc promoter significantly decreased compared to
with the CLIP3 wt-Luc promoter either in the ab-
sence or presence of NRF1, reflecting that NRF1
bound to its consensus sequence (GCGCATGCGCA)
within CLIP3 promoter region and played a role as a
transcriptional activator. Interestingly, a recent study
revealed that CDK2 activation decreased the DNA
binding activity of NRF1, which is known to be in-
duced by Spy1 [38]. Because CDK2 contributes to
radioresistance by activating S phase, we next exam-
ined the binding affinity of Spy1 and CDK2 after IR
in GBM cell lines (Fig. 2E) [39]. In immunoprecipita-
tion experiments, we found that IR caused CDK2 to
bind to HA-tagged Spy1, which implied CDK2 activa-
tion, in a time- and dose-dependent manner. There-
fore, we hypothesized that Spy1 could negatively
regulate the transcriptional level of CLIP3 by releasing
NRF1 from the CLIP3 promoter region (Fig. 2F). To
test this hypothesis, we transfected GBM cell lines
with the CLIP3 promoter, and measured luciferase ac-
tivity upon Spy1 overexpression with or without
CDK2 knockdown (Fig. 2G). Our data showed that
Spy1 overexpression increased luciferase activity, but
it was reduced with the CDK2 knockdown. We then
measured the activity upon knockdown of CDK2 only,
or both CDK2 and NRF1 (Fig. 2G). CDK2 knockdown
significantly increased luciferase activity, but an add-
itional knockdown of NRF1 decreased the activity.
Collectively, these data demonstrated that
downregulation of CLIP3 expression in GBM cells is
mediated by IR-induced Spy1 expression.
Acquisition of stemness is mediated by Spy1-CLIP3 axis in
GBM cells
Because Spy1 appears to primarily maintain GSC self-
renewal as the mechanism driving GBM cell radioresis-
tance [10], we next investigated how CLIP3 downregula-
tion impacts on stemness properties of GBM cells. After
exposure to IR or CLIP3 siRNA, flow cytometry sorted
cells were significant enriched for cells expressing
CD133 (Prominin1), a representative GSC surface
marker, (Fig. S2A). Similarly, Spy1 knockdown sup-
pressed the expression of canonical stem cell transcrip-
tion factors NANOG and OCT4 in both GBM cell lines
and patient-derived GSC11 glioblastoma stem cells
(Fig. 3A). On the other hand, CLIP3 knockdown signifi-
cantly increased NANOG and OCT4 expression (Fig.
3B). The degree of GSC stemness is reflected in capacity
to form tumor spheres in GSC culture. Indeed, in limit-
ing dilution assays using U87MG, T98G, and GSC11, we
found that the frequency of GSCs capable of forming
tumor spheres was decreased by Spy1 knockdown but
increased by CLIP3 knockdown (Fig. 3C). Taken to-
gether, CLIP3 downregulation enhances GBM stemness
without any further activation of Spy1.
CLIP3 controls plasma membrane translocation of GLUT3
in GBM cells
Given that CSCs have higher glycolytic activity than
other cancer cells, and CLIP3 is related to regulation of
glucose transmembrane transport (Fig. 1A), we next ex-
amined these functional relationships by measuring the
extracellular acidification rate (ECAR) with Seahorse
XFp analyzer. As shown in Fig. 4A, double-knockdown
of CD133 and NESTIN (NES) significantly suppressed
glycolytic rate and capacity in U87MG and T98G cells,
reflecting that glycolytic activity of GBM is highly related
to GSC enrichment. Next, we assumed that downregula-
tion of CLIP3 after IR exposure might elevate glycolytic
activity by regulating GLUTs, which are critical for
GBM cell activity. In U87MG cells, levels of both
GLUT1 and GLUT3, the major GLUTs in GBM, were
increased upon CLIP3 knockdown, while in T98G cells,
only the GLUT3 level was slightly increased (Fig. 4B).
On the other hand, CLIP3 overexpression barely de-
creased GLUT mRNA expression in U87MG cells while
levels of both GLUTs were significantly decreased by
CLIP3 transfection in the T98G cells (Fig. 4C), showing
that GLUT transcription was not completely regulated
by CLIP3 expression. As the cellular location of the
GLUTs is known to be impacted by CLIP3, we next used
immunocytochemistry after IR exposure to investigate
cellular localization of GLUTs [12, 13]. As shown in Fig.
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4D, IR considerably increased nuclear expression of
Spy1, and accordingly, membrane translocation of
GLUT3, but not GLUT1 in GBM cell lines. On the other
hand, Spy1 knockdown restricted GLUT3 membrane
localization. In a previous study, GLUT3 translocation
was mediated by the evasion of autophagic degradation
of Rab11a-positive endosome, and we therefore next ex-
amined whether IR and CLIP3 knockdown could locate
GLUT3 on the Rab11a-positive endosome. Immunocyto-
chemistry analysis shows that colocalization of Rab11a
and GLUT3 was increased after IR and CLIP3 knock-
down in GBM cell lines (Fig. 4E). Furthermore, live cell
imaging of GBM cell lines expressing GLUT3-GFP re-
vealed that both IR and CLIP3 knockdown induced
GLUT3 cell surface trafficking (Fig. 4F and Supplemen-
tary Videos S1, S2, S3, S4, S5 and S6). In summary, IR
triggers downregulation of CLIP3 which increases glyco-
lytic activity by promoting Rab11a-dependent membrane
translocation and recycling of GLUT3, the key GLUT in
GSCs.
Fig. 3 Acquisition of stemness is mediated by Spy1-CLIP3 axis in GBM cells. A mRNA levels of Spy1, NANOG, and OCT4 were analyzed by real-
time qRT-PCR upon Spy1 siRNA treatment in U87MG, T98G, and GSC11 cells. B mRNA levels of CLIP3, NANOG, and OCT4 were analyzed by real-
time qRT-PCR upon CLIP3 siRNA treatment in U87MG, T98G, and GSC11 cells. C In vitro limiting dilution assays of U87MG, T98G, and GSC11 cells
treated with Spy1 or CLIP3 siRNA. The frequency of GSCs was calculated by extreme limiting dilution assay (ELDA) analysis. *p < 0.05, **p < 0.01,
***p < 0.001 with unpaired t-test
Kang et al. Journal of Experimental & Clinical Cancer Research          (2021) 40:282 Page 9 of 18
Spy1-CLIP3 axis contributes to metabolic shift toward
glycolysis in GBM cells
To determine whether Spy1 and CLIP3 directly control
glycolytic activity, we tested the oxygen consumption
rate (OCR) and ECAR in the GBM cell lines (U87MG
and T98G) and patient-derived glioblastoma stem cells
(GSC11, BCL20-HP01, and BCL20-HP02). After Spy1
knockdown, both basal OCR and ATP production were
Fig. 4 CLIP3 controls plasma membrane translocation of GLUT3 in GBM cells. A ECAR was measured by Seahorse analyzer upon transfection of
both CD133 and NES siRNA in U87MG and T98G cells. Bar graphs depict glycolysis (measured by the generation of lactate upon glucose addition)
and glycolytic capacity (the maximum capacity of lactate generation upon inhibition of oxidative phosphorylation). 2-DG, 2-Deoxy-D-glucose. B
mRNA levels of CLIP3, GLUT1, and GLUT3 were analyzed by real-time qRT-PCR upon CLIP3 siRNA treatment in U87MG and T98G cells. C mRNA
levels of CLIP3, GLUT1, and GLUT3 were analyzed by real-time qRT-PCR upon transfection of CLIP3 gene in U87MG and T98G cells. D
Representative immunofluorescence staining for Spy1 (red), GLUT3 (green), and merged images (with DAPI, blue) on Control, IR (6 Gy), or Spy1
siRNA treatment in U87MG and T98G cells. Scale bars, 10 μm. E Representative immunofluorescence images for Rab11a-OFP (red), GLUT3-GFP
(green), and merged images on Control, IR (6 Gy), or CLIP3 siRNA treatment in U87MG and T98G cells. Scale bars, 10 μm. F Confocal live-cell
images of U87MG and T98G cells stably expressing GLUT3-GFP after treatment of IR (6 Gy) or CLIP3 siRNA for the indicated times. Arrows indicate
GLUT3-GFP-containing vesicular structures migrating toward the plasma membrane. Scale bars, 5 μm. *p < 0.05, **p < 0.01, ***p < 0.001 with
unpaired t-test
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Fig. 5 (See legend on next page.)
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increased, whereas glycolytic rate and capacity were
downregulated (Fig. 5A and S3A). Conversely, CLIP3
knockdown decreased basal OCR and ATP production,
and increased glycolytic rate and capacity (Fig. 5B and
S3B). We then measured major intermediates of glucose
metabolism (Fig. S4A) in U87MG cells after IR exposure,
Spy1 overexpression, CLIP3 knockdown, IR with Spy1
knockdown, or IR with CLIP3 overexpression (Fig. S4B-
S4E). As shown in Fig. S4B, both glucose uptake and lac-
tate production were elevated after IR, Spy1 overexpres-
sion, or CLIP3 knockdown, but were restored by IR with
Spy1 knockdown or IR with CLIP3 overexpression.
Similarly, in Fig. S4C, glycerol-3-phosphate and serine
levels were also increased in the elevated groups, but
the NADP+/NADPH ratio was reduced, which would
mean that glycolysis-related pathways and the pentose
phosphate pathway were also activated by IR, Spy1, or
CLIP3 knockdown. We also found that production of
citric acid cycle intermediates was decreased after IR,
Spy1 overexpression, or CLIP3 knockdown, and res-
cued by IR with Spy1 knockdown or IR with CLIP3
overexpression (Fig. S4D). In Fig. S4E, we forced the
cells to undergo either glycolysis or oxidative phos-
phorylation. ATP levels were not significantly changed
in normoxic conditions across all groups, but in hyp-
oxic conditions, ATP levels were increased after IR in
cells with Spy1 overexpression or CLIP3 knockdown,
but were almost restored to control levels after IR
with Spy1 knockdown or CLIP3 overexpression. Con-
versely, upon glucose deprivation, we found that cell
numbers were significantly decreased after IR in cells
with Spy1 overexpression or CLIP3 knockdown due
to glycolytic dependency, but cell numbers signifi-
cantly recovered after IR in cells with Spy1 knock-
down or CLIP3 overexpression. Taken together, our
data are consistent with an IR response in which
GBM cells switch glucose metabolism towards gly-
colysis through Spy1 activation and CLIP3 inhibition.
Glimepiride disrupts GSC maintenance and glycolytic
activity by CLIP3 activation
We next investigated drugs that could regulate the
Spy1-CLIP3 axis. Because the expression of CLIP3, but
not Spy1, constantly changed after IR, we focused on
CLIP3 activating drugs that might have a capacity for in-
creasing GBM cell radiosensitivity. To this end, we
interrogated The Connectivity Map (CMap), a database
of drug-induced gene expression profiles, to discover
candidates among existing drugs [40]. Of the many can-
didates, glimepiride, which was FDA-approved in 1995
for type 2 diabetes mellitus, significantly increased tran-
scriptional levels of CLIP3 [41]. Because glimepiride is
known to bind to and close ATP-sensitive K+ (KATP)
channels, including the inward-rectifier potassium chan-
nel 6.2 (Kir6.2), we investigated not only the effect of gli-
mepiride as a radiosensitizer but also that of Kir6.2
knockdown or glibenclamide belonging to second-
generation sulfonylurea such as glimepiride [42]. First,
we verified whether glimepiride (1 μM), glibenclamide
(1 μM), or Kir6.2 knockdown with IR exposure could re-
store CLIP3 transcription and attenuate that of NANOG
and OCT4 to reduce radioresistance (Fig. 6A). Of the
three different treatments, only glimepiride was able to
significantly increase CLIP3 mRNA level and decrease
NANOG and OCT4 mRNA levels after IR in GBM cell
lines. Similarly, in patient-derived GSC11 glioblastoma stem
cells, glimepiride significantly increased CLIP3 expression
and reduced NANOG and OCT4 expression without IR ex-
posure due to its high intrinsic radioresistance (Fig. S5A).
We next tested the effect of IR on glimepiride sensitivity
using CellTiter-Glo® Luminescent Cell Viability Assay (Fig.
6B). IR significantly improved glimepiride sensitivity of both
U87MG and T98G cell lines. IR reduced the IC50 of glime-
piride from 22.44 μM to 6.20 μM in U87MG cells and from
20.34 μM to 7.70 μM in T98G cells. Additionally, we further
examined synergistic effects of IR and glimepiride (0.1 and
1 μM) by colony-forming assay. Glimepiride did not reduce
colony-forming ability in non-irradiated cells, but with IR,
unlike the cell viability assay, which showed little cytotoxicity
at 1 μM, colony-forming ability was significantly reduced by
1 μM of glimepiride with IR in U87MG and T98G cells, pre-
sumably because glimepiride disrupted GSCs maintenance
(Fig. 6C). Furthermore, the combination therapy reduced
glucose uptake and lactate production compared with IR
only (Fig. S6A and S6B). These data suggest that glimepiride
acts as a radiosensitizer by suppressing stemness and glycoly-
sis in GBM cells. To further validate these results, we exam-
ined effect of glimepiride on the patient-derived glioblastoma
stem cells (GSC11, BCL20-HP01, and BCL20-HP02) (Fig.
6D and E). As shown in Fig. 6D, glimepiride (1 μM) signifi-
cantly reduced sphere-forming ability, but this effect was di-
minished with CLIP3 knockdown. Similarly, the glycolytic
(See figure on previous page.)
Fig. 5 Spy1-CLIP3 axis contributes to metabolic shift toward glycolysis in GBM cells. A, B OCR and ECAR were measured by Seahorse analyzer in
U87MG, T98G, and GSC11 cells. Basal OCR indicates the basal level of oxygen consumption and ATP production indicates the decrease in oxygen
consumption rate upon injection of oligomycin, which represents the portion of basal respiration that was being used to drive ATP production.
Glycolysis indicates the generation of lactate upon glucose addition and glycolytic capacity indicates the maximum capacity of lactate generation
upon inhibition of oxidative phosphorylation. OCR and ECAR upon transfection of Spy1 siRNA (A) or CLIP3 siRNA (B). *p < 0.05, **p < 0.01, ***p <
0.001 with unpaired t-test
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rate and capacity were markedly decreased upon glimepiride
treatment (1 μM), but it was not able to change ECAR with-
out CLIP3 expression in all three GSCs (Fig. 6E). Taken
together, our data show that glimepiride can disrupt GSC
maintenance and glycolysis, and overcome radioresistance by
activating CLIP3.
Combination of glimepiride with IR improves survival of
GBM-bearing mice
To examine effects of glimepiride in vivo and compare the
effects with the first-line drug TMZ, U87MG (MGMT
negative) was used instead of T98G (MGMT positive).
We implanted U87MG-luciferase expressing cells
(U87MG-luc) orthotopically in BALB/c nude mice
(Fig. 7A). The mice were treated with IR alone, or IR in
combination with glimepiride or TMZ two weeks after the
orthotopic xenograft. In vivo bioluminescent imaging
showed that IR/glimepiride combination treatment signifi-
cantly inhibited tumor growth and conferred a marked
survival benefit in comparison to untreated control (28
days of median survival) or IR-alone (33 days of median
survival), and was even as effective as TMZ combined
with IR (Fig. 7B and C). Furthermore, even though glime-
piride is a diabetic medicine, the body weight of the mice
hardly changed, indicating little side effect (Fig. S7A). To
verify the lack of tumor growth and measure protein ex-
pression in vivo, we conducted a histological analysis of
the brain tissue. Consistent with the in vitro analysis, ex-
pression and nuclear localization of Spy1 were highly
increased by IR, and IR/glimepiride combination therapy
strongly suppressed tumor growth, but also activated
CLIP3 expression, resulting in radiosensitivity (Fig. 7D).
Collectively, our preclinical data show that activation of
CLIP3 by glimepiride is a mechanism that counteracts
(See figure on previous page.)
Fig. 6 Glimepiride disrupts GSC maintenance and glycolytic activity by CLIP3 activation. A mRNA levels of CLIP3, NANOG, and OCT4 were
analyzed by real-time qRT-PCR upon treatment of IR (6 Gy), IR with Kir6.2 siRNA, IR with glimepiride (1 μM), or IR with glibenclamide (1 μM) in
U87MG and T98G cells. B IC50 of glimepiride with or without IR in U87MG and T98G cells was measured by CellTiter-Glo® Luminescent Cell
Viability Assay. Cells were treated with increasing concentrations of glimepiride and/or IR (6 Gy) for 48 h. C Colony-forming ability was evaluated
using colony-forming assay after treatment of glimepiride (0.1 and 1 μM) with or without IR (6 Gy) (data represent mean of n = 3 dishes). D In
vitro limiting dilution assays of GSC11, BCL20-HP01, and BCL20-HP02 cells treated with glimepiride (1 μM) or glimepiride with CLIP3 siRNA. The
frequency of GSCs was calculated by extreme limiting dilution assay (ELDA) analysis. E ECAR was measured by Seahorse analyzer upon treatment
of glimepiride (1 μM) (upper panel), and treatment of CLIP3 siRNA with or without glimepiride (lower panel) in GSC11, BCL20-HP01, and BCL20-
HP02 cells. Statistical analysis was performed with one-way ANOVA plus a Tukey’s multiple comparisons test for (A) and (C), and Student’s t-test
for (E). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (compared to control). #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 (compared to IR)
Fig. 7 Combination of glimepiride with IR improves survival of GBM-bearing mice. A A schematic diagram of control, IR (2 Gy × 5), IR with
glimepiride (5 mg/kg, oral), and IR with temozolomide (20 mg/kg, i.p.) treatment in mice bearing U87MG-luciferase xenografts (n = 20 mice per
group). B In vivo bioluminescent images of orthotopic xenografts derived from U87MG-luciferase in mice control, treated with IR, IR with
glimepiride, or IR with temozolomide. C Survival analysis by Kaplan-Meier curves and log-rank (Mantel-Cox) test of mice bearing U87MG-luciferase
xenografts control, treated with IR, IR with glimepiride, or IR with temozolomide. D Hematoxylin and eosin (H&E) staining (upper panel) and
immunohistochemistry (anti-Spy1 and anti-CLIP3; middle and lower panel) of coronal sections from mice bearing U87MG-luciferase xenografts
control, treated with IR, or IR with glimepiride. Scale bars, 2000 μm (upper) or 50 μm (lower). E Schematic diagram depicting that CLIP3 activation
by glimepiride impairs radioresistance of GSCs
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radioresistance and improves survival of the GBM-bearing
mice by targeting GSCs.
Discussion
The standard of care for patients diagnosed with GBM
has long entailed tumor resection, followed by radiother-
apy and concomitant TMZ [24]. Despite this aggressive
treatment regimen, long-term survival remains poor due
to the persistence of radioresistant GSCs [43, 44]. Other
approaches in development include immunotherapies,
which have been gamechangers in heme malignancies
but disappointed in solid tumors such as GBM [45], and
oncolytic virus, which has shown promise when com-
bined with immunotherapies [46]. However, directly tar-
geting GSCs remains extremely challenging and there
are still no approved drugs targeting GSCs [6].
Metabolic targeting of CSCs is being proposed as a
new paradigm of cancer therapy [47]. To date, most
clinical trials related to CSC metabolism have focused
on targeting metabolic enzymes [17]. However, this ap-
proach is often toxic to normal cells, and accordingly,
very few such drugs have been approved for clinical use
[48]. In this study, we proposed to regulate glucose up-
take by targeting GLUT3 trafficking in GBM cells. This
strategy is in line with a recent study demonstrating that
inhibiting Tubulin beta-4A chain (TUBB4) reduces levels
of GLUT1, found to be overexpressed in astrocytoma,
and inhibits self-renewal and tumor-initiating capacity in
GSCs, although TUBB4 inhibition might well negatively
impact on important cellular functions as well [49].
Interestingly, in contrast with GLUT1, GLUT3 expres-
sion is primarily elevated in GSCs and its expression
highly correlates with poor survival in GBM [19], sug-
gesting that targeting GLUT3 would more specifically
disrupt GSCs. However, a recent study showed that a
GLUT3 inhibitor induced cytotoxicity with the effective
inhibition dose (50 μM) due to its general expression in
neurons, indicating that directly inhibiting GLUT3 might
induce serious side effects [50]. More broadly, glucose
transporters are central to neuronal glucose uptake and
brain metabolism, and targeted therapies will therefore
need to take into account potential unwanted side effects
[51]. In this context, the indirect mechanism we delin-
eated here suggests that targeting CLIP3 to suppress
GLUT3 cell surface trafficking would primarily effect
CLIP3-expressing GBM cells such as GSCs.
GLUTs are continuously internalized by endocytosis
and recycled to the cell membrane, so both transcrip-
tional levels and recycling kinetics regulate the rate of
glucose uptake [21]. To date, GLUT trafficking research
has been heavily focused on GLUT4, which is mainly
stimulated by insulin-derived signals up to 10 times that
of baseline levels [20]. However, GLUT3 recycling and
its cell surface level are known to be regulated by
Rab11a, a member of the Rab family, mostly involved in
vesicle trafficking including endosome recycling for sev-
eral GLUTs [22]. According to our data, CLIP3 reduced
GLUT3 membrane trafficking by disrupting the Rab11a-
positive endosome, which was consistent with previous
studies that CLIP3 contains a CAP-Gly domain, which is
involved in vesicle and organelle transportation along
the cytoskeletal network [52]. We anticipate that further
studies by verifying binding partners involved in CLIP3-
mediated GLUT3 translocation will identify cytoskeletal
molecules for targeting GSCs.
Glimepiride is an FDA-approved oral drug for the
treatment of type 2 diabetes mellitus with an accept-
able side effect profile and classified as a second-
generation sulfonylurea [41]. Sulfonylureas are organic
compounds which close the KATP channels and open
voltage-gated Ca2+ channels to increase the calcium
influx, not only in pancreatic beta cells but also cells
in other tissues, including the heart and brain [53].
Our in vitro data demonstrate that glimepiride signifi-
cantly attenuates IR-induced gene expression changes,
whereas inhibition of the KATP channel or glibencla-
mide did not. These different effects are likely ex-
plained by the different binding affinity of the two
sulfonylureas. Because glimepiride has a 2.5 to 3-fold
lower affinity to the KATP channel than glibenclamide,
glimepiride might employ another molecular mechan-
ism to regulate GSCs [54]. Although it is known that
sulfonylureas do not effectively penetrate the blood-
brain barrier (BBB), recent studies showed that glime-
piride is able to cross the BBB and affect the brain
under diabetic or stroke conditions where the BBB in-
tegrity is compromised [55]. Because BBB disruption
is one of the common characteristics of GBM, these
findings lend support to glimepiride having potential
as a drug candidate for GBM and could even be or-
ally administered as in diabetes treatment [56]. In-
deed, our in vivo data indicate that glimepiride was
delivered to the brain and acted as a radiosensitizer
in GBM.
Our preclinical data demonstrate that glimepiride im-
proves survival of GBM-bearing mice as effectively as
TMZ when combined with IR even using the MGMT
negative cell line, U87MG, with an efficacy more signifi-
cant than predicted by our in vitro data. A recent clinical
study showed that diabetic patients with GBM had
poorer overall survival due to hyperglycemia [57]. Be-
cause glimepiride can induce insulin secretion to reduce
blood glucose levels as well as CLIP3 activation, a de-
crease in blood glucose levels upon treatment of glime-
piride might explain the significant in vivo efficacy in
GBM mouse models. In addition, TMZ is highly toxic,
whereas glimepiride side-effects are more manageable,
and in combination with IR could therefore potentially
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achieve similar therapeutic efficacy with less burden to
patients [58]. Further clinical studies are needed in order
to optimize the dosage, the duration of the drug in hu-
man applications and the potential for using CLIP3 as a
GBM biomarker.
Conclusions
In this study, we identified the Spy1-CLIP3 axis as a crit-
ical regulator of GSC maintenance. We found that Spy1
was increased after IR and enhanced stemness by acti-
vating nuclear CDK2 in GBM cells. Mechanistically,
CDK2 prevents NRF1 from binding to the promoter re-
gion of CLIP3, keeping CLIP3 transcription low after IR.
Downregulation of CLIP3 in turn induces GLUT3 traf-
ficking to cellular membranes and increases glycolytic
activity, especially in GSCs. Importantly, our data dem-
onstrate that the CLIP3 activator glimepiride targets
GSC metabolism. Overall, this study suggests that radio-
resistant GBM cells that survive after radiotherapy ex-
hibit increased stemness and glycolytic activity mediated
by the Spy1-CLIP3 axis, and that glimepiride by activat-
ing CLIP3 can achieve high-efficiency radiosensitization
with low toxicity (Fig. 7E). Clinical trials with glimepir-
ide for GBM patients might improve survival, especially
for patients who have suffered from recurrence after
radiotherapy.
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